What conditions do your treatments address?

Vibrant, LLC was founded by a physician-scientist with over 20 years of research experience developing muscle progenitor cell therapies and biologic drugs to restore muscle function following laryngeal nerve injury. After achieving strong results in preclinical models of laryngeal paralysis, we are now expanding our research to explore the use of these therapies for muscle loss and dysfunction caused by nerve damage in other regions of the body. Over the next five years, Vibrant aims to continue advancing preclinical studies focused on muscle deterioration related to denervation, trauma, and aging—paving the way toward future clinical applications and delivering on our vision of vibrant muscles and vibrant lives.

Are treatments personalized for each patient?

While Vibrant, LLC is currently focused on preclinical research, our goal is to develop highly personalized therapies for future clinical use. Our lead cell therapy platform begins with a small muscle biopsy from the patient, from which muscle progenitor cells are expanded using a patented culture method. This process enhances the cells’ ability to release nerve- and blood vessel–attracting factors, enabling them to promote reinnervation, revascularization, and repair of weakened muscle when injected back into the site of injury.

In addition to our patient-derived cell therapies, we are also developing novel injectable biologic treatments that eliminate the need for muscle biopsy or cell culturing. These biologics are designed to activate the patient’s own muscle-resident cells, stimulating the release of the same regenerative factors that drive nerve and vessel growth, ultimately supporting muscle recovery and function.

What sets your company apart from other drug development firms?